Related Experiment Video
Updated: Sep 2, 2025
05:31
Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
3.0K
Preliminary Report from a Randomized Controlled Trial Comparing Two Bovine Pericardial Valves
Suk Ho Sohn1, Ji Seong Kim1, Jae Woong Choi1
1Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul, Republic of Korea.
The Thoracic and Cardiovascular Surgeon
|August 2, 2022
Summary
A new bovine pericardial valve for aortic valve replacement showed comparable early hemodynamic and clinical outcomes to the widely used control valve. This preliminary analysis supports the safety and efficacy of the novel bioprosthesis.
Area of Science:
- Cardiovascular Surgery
- Biomedical Engineering
- Clinical Trials
Background:
- Aortic valve replacement (AVR) is a critical procedure for managing aortic valve disease.
- Bioprosthetic valves are commonly used, with ongoing development of new designs.
- This study compares a novel bovine pericardial bioprosthesis with a standard one.
Purpose of the Study:
- To compare 1-year hemodynamic profiles and clinical outcomes after AVR.
- To evaluate the early postoperative performance of a new bovine pericardial bioprosthesis.
- To assess the noninferiority of the study valve compared to the control valve.
Main Methods:
- A randomized controlled trial was conducted.
- 70 patients were enrolled in each group (study vs. control).
- Primary endpoint: mean pressure gradient across the aortic valve (AVMPG) at 1 year; early outcomes were also analyzed.
Main Results:
- No significant differences in baseline characteristics were observed.
- Early postoperative AVMPG was similar between groups (15.2 ± 4.6 mm Hg vs. 16.5 ± 6.2 mm Hg).
- No significant differences in effective orifice area or index, operative mortality, or complications were found.
Conclusions:
- Early hemodynamic and clinical results of the new bovine pericardial valve are comparable to the control valve.
- The recently introduced bioprosthesis demonstrates similar early performance.
- Further follow-up is needed to confirm long-term outcomes.
